Please login to the form below

Competition from within

Published in eyeforpharma July 29 by Rachel Howard
To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/





25th August 2015

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Article
Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma
Research Partnership
Infographic
Migraine market snapshot
Research Partnership
Webinar
Monitoring the impact of COVID-19 on the market access landscape
Research Partnership
Live webinar from Singapore
Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19
Research Partnership
Guide
UX research
Research Partnership
Article: Why pharma must trust the science of behaviour

Research Partnership